KLRG1 Monoclonal Antibody (13F12F2), Functional Grade, eBioscience™, Invitrogen™

Description

This 13F12F2 monoclonal antibody reacts with human killer cell lectin-like receptor subfamily G, member 1 (KLRG1), a type II transmembrane inhibitor receptor of the C-type lectin superfamily that contains an ITIM domain. This inhibitory receptor is expressed on subsets of gamma-delta T cells, NK (CD56dim), CD8+ and CD4+ T Cells. KLRG1 is expressed primarily by cells with an effector/memory phenotype that are short-lived, but capable of immediate effector cell function. Cadherin-E, -N, and -R are ligands for KLRG1. Cadherin/KLRG1 interaction inhibits cytolytic activity and proliferation. The percentage of KLRG1 positive cells can vary considerably, depending on antigen experience. The clones 13F12F2 and 13A2 appear to recognize a similar epitope based on cross-blocking studies. This 13F12F2 antibody has been tested by flow cytometric analysis of human peripheral blood cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount ( μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/ μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

KLRG1 (Killer cell lectin-like receptor G1, MAFA, 2F1-Ag) is a homodimeric member of the lectin-like type 2 transmembrane receptor family whose members contain characteristic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domains. These ITIMs interact with the SH2 domains of protein phosphatases such as SHP-1. KLRG1 is an inhibitory receptor that is expressed on natural killer (NK) cells and certain T cells. NK cells are involved in the lysis of tumor cells and virus-infected cells, and mediate humoral and cell-mediated immune responses.